To evaluate the therapeutic effect of bevacizumab in treating myopic choroidal neovascularization (CNV).

Medical records of the eyes that underwent intravitreal bevacizumab injection for myopic CNV and were followed up for more than one year were reviewed retrospectively. Best corrected visual acuity (BCVA), foveal thickness in optical coherence tomography and fluorescein angiography were investigated.

Twenty eyes of 18 patients were included in the present study. The average age was 41.5 years, average axial length was 28.5 mm, and average refractive error was -11.0 diopters. Visual acuity was maintained in all eyes, and 13 eyes improved by LogMAR 0.3 or more. Visual acuity improved significantly from 0.71 (0.2~2.0) to 0.40 (0.1~2.0, p =0.02) at six months and to 0.41 (0.1~2.0, p =0.03) at one year. Central foveal thickness significantly decreased from 247.0 µm to 207.5 µm ( p =0.03) at six months and to 208.5 µm ( p =0.04) at one year.

Anti-VEGF therapy using bevacizumab for the treatment of myopic CNV was effective in maintaining visual acuity.